{
  "id": 20153917,
  "title": "United Therapeutics CEO Martine Rothblatt sells $4.77M in stock",
  "url": "https://urgent.news/2026/11/15/united-therapeutics-ceo-martine-rothblatt-sells-4-77m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-15T09:31:31.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/united-therapeutics-ceo-martine-rothblatt-sells-477m-in-stock-93CH-5027773"
  },
  "original_language": "en",
  "account": "United Therapeutics CEO Martine Rothblatt sold 9,500 shares of the company's stock on September 15, 2026, amounting to about $4.77 million in proceeds. These transactions were part of a pre-arranged 10b5-1 trading plan she established in November 2025. Rothblatt initially purchased the shares at $117.76 each, totaling $1,118,720, with the options vesting one-third at a time between March 2021 and March 2023. The sale took place in multiple trades at prices between $499.24 and $505.04 per share, with the company's stock currently trading at $591.17 and nearing its 52-week high of $614.23. Rothblatt's overall ownership in United Therapeutics now stands at 40,513 shares directly and 628,215 shares indirectly held through family trusts. Despite the stock appearing overvalued relative to its Fair Value estimate, United Therapeutics posted record third-quarter revenue of $832.5 million, exceeding analyst estimates. The company's Tyvaso revenue grew by 11% quarter-over-quarter and 5% year-over-year, outperforming expectations. Investors can explore more details about United Therapeutics through the Pro Research Report on InvestingPro.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}